Dr. Da Silva is Principal Investigator on a newly awarded pilot project funded by an American Cancer Society Institutional Research Grant (ACS IRG-58-007-54)!!
The focus of Dr. Da Silva’s ACS-funded work is to investigate and develop immunotherapeutic strategies against human papillomavirus-induced cancers through exploration of potential synergistic effects with immune checkpoint blockade and therapeutic vaccines combined with standard chemotherapy in the context of cervical cancer. Given that cervical cancer is a gynecologic disease causing significant morbidity and mortality worldwide, progress in this area has the potential to significantly improve clinical outcomes for patients with advanced-stage cervical cancer.
We are very proud of her accomplishment and are excited to see this work move forward!